Private insurance coverage and living closer to a plastic surgeon’s office encouraged women who had a mastectomy to undergo breast reconstruction, according to a recent study.
Private insurance coverage and living closer to a plastic surgeon’s office encouraged women who had a mastectomy to undergo breast reconstruction, according to a new study by researchers at the University of North Carolina Lineberger Comprehensive Cancer Center.
Breast reconstruction following a mastectomy can boost a woman’s quality of life by influencing her self-esteem, body image, and sexuality. Despite these benefits, women often face socioeconomic and demographic barriers to such services. To better understand the correlation between density of plastic surgeons and health insurance with the rate of breast reconstruction surgery in North Carolina, researchers at the University of North Carolina at Chapel Hill conducted retrospective analysis of data from the Integrated Cancer Information and Surveillance System, which links the North Carolina Central Cancer Registry to beneficiaries in Medicare, Medicaid, and private insurance plans across the state.
“We know that breast cancer affects not only the physical wellbeing of the patient, but also her psychosocial wellbeing, and we know that breast reconstruction can help address those issues,” said first author of the study Michelle Roughton, MD, assistant professor of surgery and program director for the UNC School of Medicine Section of Plastic and Reconstructive Surgery.
After applying inclusion and exclusion criteria to more than 27,638 cases diagnosed between 2003 and 2006, the final cohort included 5381 patients. Exclusion criteria included inflammatory disease, death or autopsy, distant metastatic disease, multiple breast cancers, no mastectomy, mastectomy performed 6 months after diagnosis, and patients who were simultaneously enrolled in Medicaid, Medicare, and private insurance.
The analysis found that 20% of women in the cohort being studied underwent postmastectomy breast reconstruction. Receipt of reconstruction was significantly associated with distance to the breast reconstructive surgeon: 10 miles or less seemed conducive to undergoing the operation; women living between 10 and 20 miles from a surgeon had 22% lower odds of a breast reconstruction (odds ratio [OR], 0.78; 95% CI, 0.63 to 0.96), while those living more than 20 miles from a surgeon had 27% lower odds (OR, 0.73; 95% CI, 0.57 to 0.93) compared with women who lived within a 10-mile radius.
Insurance was another looming factor. Women enrolled in Medicare (OR, 0.58; 95% CI, 0.45 to 0.74) or Medicaid (OR, 0.24; 95% CI, 0.19 to 0.32) had lower odds of undergoing reconstruction compared with those who paid for private insurance coverage. A racial bias was also observed, with white women more likely to choose the reconstruction option.
“As doctors working for the state’s flagship cancer hospital, we aim to provide breast reconstruction to every woman who desires it despite distance and payer,” Roughton said, sharing that telemedicine and digital communications such as e-mail and text messaging was being used at their cancer hospital, at least for the initial consultations.
Reference
Roughton MC, DiEgidio P, Zhou L, Stitzenberg K, Meyer AM. Distance to a plastic surgeon and type of insurance plan are independently predictive of postmastectomy breast reconstruction. Plast Reconstr Surg. 2016;138(2):203e-211e. doi: 10.1097/PRS.0000000000002343.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More